Low-intensity shockwave versus daily solifenacin for women's overactive bladder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this randomized Phase 4 trial adult women with overactive bladder are assigned to receive either once-weekly low-intensity shockwave therapy for 8 weeks or oral solifenacin 5 mg daily for 12 months. Participants complete symptom questionnaires and three-day bladder diaries and undergo uroflowmetry, post-void residual measurement, and filling cystometry at scheduled visits. The study follows patients for up to 12 months to see how symptoms and quality of life change and whether any benefits are sustained. Safety and tolerability of Li-SWT are monitored and compared with standard medical therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* OAB symptoms persisting for ≥3 months.
* OAB Symptom Score (OABSS) ≥7.
* Ability and willingness to provide informed consent

Exclusion Criteria:

* Active urinary tract infection.
* Stress urinary incontinence as primary diagnosis.
* Pelvic organ prolapse stage ≥II.
* History of pelvic radiation or surgery within 6 months.
* Use of anticholinergics or β3-agonists for the past 4 weeks who are unwilling to undergo washout.
* Pregnancy or breast feeding.
* Neuropathic diseases or psychological disorders.
* History of urogenital malignancy.
* Uncontrolled DM (HbA1c \> 6.8)
* Uncorrected coagulopathy or severe cardiovascular disease.
* Contraindication to solifenacin e.g.: closed angle glaucoma)

Where it's running

• Mansoura Faculty of medicine
  Al Mansurah, Dakahlia Governorate, Egypt Recruiting

Study contacts

• Study coordinator: Yahya H Elmorsy
• Email: Hossam.Yahya@yahoo.com
• Phone: 00201100311999

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Genitourinary microbiome before and after Botox bladder injections in postmenopausal women

  We're trying to see if the bacteria in the urine change in postmenopausal women with overactive bladder before and four weeks after Botox bladder injections.

  Recruiting Medstar Health Research Institute · Washington D.C., District of Columbia · NCT07025044

• Predictive value of inflammatory biomarkers for mirabegron response in women with overactive bladder

  This study tests whether baseline blood inflammation markers can predict how well women with OAB respond to mirabegron after 3 months.

  Recruiting Bagcilar Training and Research Hospital · Istanbul, Bagcilar · NCT07773532

• NT 201 therapy delivered via the Vibe System for idiopathic overactive bladder

  This Phase 2b trial tests NT 201 given with the Vibe System to see if it helps adults with idiopathic overactive bladder compared to placebo or sham treatment.

  Recruiting at 3 sites Phase 2 Vensica Therapeutics Ltd. · Margate, Florida and 2 other locations · NCT07553065

• Ambulatory tibial nerve stimulation for overactive bladder in adults

  A portable nerve-stimulation device used at home is being tested to see if it can reduce urgency and improve bladder symptoms in adults with overactive bladder.

  Recruiting Başakşehir Çam & Sakura City Hospital · Istanbul, Istanbul · NCT07540273

• Low-dose tadalafil versus solifenacin for treating overactive bladder in women

  This trial will test whether taking daily low-dose tadalafil or daily solifenacin reduces overactive bladder symptoms in women aged 18–75.

  Recruiting at 14 sites Phase 4 Mansoura University · Shibīn al Kawm, Al-Minūfiyyah and 13 other locations · NCT07416968

• Zinc plus phytase given before botulinum toxin injections for overactive bladder

  This trial will test whether a short course of oral zinc plus phytase before botulinum toxin bladder injections helps adult women with overactive bladder go longer without needing another injection over six months.

  Recruiting Phase 2 Endeavor Health · Skokie, Illinois · NCT07405554

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.